Clinical trials
Alzheimer Dementia (AD) clinical trials
Below are recruiting alzheimer dementia (ad) clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06335836Recruiting
Social connections and brain health in memory decline
This study looks at how being socially isolated or socially active affects memory and brain health in people who feel their thinking is getting worse. You may join if you notice a slow decline in memory or thinking, but otherwise have normal test results.
Nanjing, China, JiangsuAges 45–85 - NCT07752784RecruitingPhase 3
Tau brain imaging in people with mild thinking changes or Alzheimer's
This study uses a special PET scan to take pictures of abnormal tau protein in the brain. It aims to see if the scan results match what is found in brain tissue after death, which could help improve diagnosis of Alzheimer's and related conditions.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07580703RecruitingPhase 1
Brain Imaging Study for Memory and Thinking Changes
This study tests a new type of brain scan (called [18F]Flortaucipir PET) that may help detect early signs of Alzheimer's disease. Researchers want to make sure the scan is safe and works well in Chinese patients aged 50–85 with normal thinking, mild memory problems, or Alzheimer's disease.
Beijing, Beijing MunicipalityAges 50–85 - NCT07323914RecruitingPhase 3
Pain management for people with Alzheimer's and chronic pain
This study tests if opioid pain medicine is safe and effective for people with Alzheimer's disease who also have chronic pain. It aims to find better ways to manage pain in dementia.
BeijingAges 50–90 - NCT07191821Enrolling by invitationPhase 2
TSPO modulation for Alzheimer's disease
This trial tests a drug that targets a brain protein called TSPO in people with mild to moderate Alzheimer's. It aims to see if this approach can slow memory loss.
LondonAges 18–90 - NCT07115238RecruitingPhase 3
PET imaging study for normal aging, MCI, and Alzheimer's
This trial tests a new PET imaging agent (18F-XTR006) to see how well it shows brain changes related to Alzheimer's disease. It may help diagnose MCI (mild cognitive impairment) or Alzheimer's earlier by comparing images in healthy people and those with memory problems.
Beijing, Beijing MunicipalityAges 50 years+ - NCT06618872Recruiting
Comparing tau and amyloid PET scans for memory problems
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
Geneva, Canton of GenevaAges 50–85 - NCT04396873RecruitingPhase 1
PET brain scan study of inflammation markers in neurodegeneration
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
Bethesda, MarylandAges 18–99 - NCT07835399Recruiting
Light therapy for mild cognitive impairment and mild Alzheimer's disease
This trial tests if shining a special light through the scalp and nose can help people with mild memory or thinking problems. It aims to slow down memory decline and improve daily life.
BeijingAges 50–85 - NCT06923007Recruiting
Vagus nerve stimulation for Alzheimer's disease
This trial tests if a nerve stimulation device can help people with mild to moderate Alzheimer's. It is for patients aged 50 to 80 who are on a stable medication.
BeijingAges 50–80 - NCT06230783Recruiting
Speech test for early Alzheimer's detection
This trial uses speech pattern analysis to detect early signs of Alzheimer's. If you're already in a Wisconsin Alzheimer's study, you may help test if your voice can reveal memory changes.
Madison, WisconsinAges 40–80 - NCT06953167Recruiting
Dementia study for older adults with prior brain checks
This study follows older adults who have already had amyloid testing, to track changes in memory and thinking over time. It helps researchers understand how to prevent dementia.
LondonAges 65 years+ - NCT04335994Recruiting
Home sleep testing for people with memory trouble
This study looks at how well home sleep apnea testing works for people with cognitive impairment (memory/thinking problems) to help improve outcomes. You may be asked to do a home sleep test (and possibly an in-lab test) and will involve a caregiver if needed.
Toronto, OntarioAges Any age - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Birmingham, AlabamaAges 55–90 - NCT06781333RecruitingPhase 2
Stem cells for behavior problems in Alzheimer's
This trial tests whether a single infusion of human mesenchymal stem cells (hMSC) can improve difficult behaviors like agitation, anxiety, or hallucinations in people with Alzheimer's disease. It's designed for those who have been taking antipsychotic medication for at least 4 weeks and have a study partner to help track behavior changes.
Miami, FloridaAges 55–90 - NCT07646054Enrolling by invitation
Lifestyle coaching for preventing Alzheimer's in APOE4 carriers
This study tests a digital lifestyle coaching program designed to help prevent Alzheimer's disease in people who carry the APOE4 genetic variant, which increases risk. Over one year, you'll get personalized health coaching through apps and possibly a smart ring to track your progress.
La Jolla, CaliforniaAges 60–80 - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT07764679RecruitingPhase 3
Brain scan to detect Alzheimer's plaques
This study tests a new PET brain scan that uses a special dye to show amyloid plaques, which are linked to Alzheimer's disease. It may help doctors see if your memory problems are caused by Alzheimer's or something else.
Beijing, Beijing MunicipalityAges 40 years+ - NCT07222449Enrolling by invitation
Wearable devices and blood tests for sleep in Alzheimer's
This study uses wrist monitors and blood tests to understand sleep problems in people with Alzheimer's dementia. It aims to improve sleep management through digital therapy and personalized insights.
Beigang, YunlinAges Any age - NCT06855368Recruiting
Biomarkers for tracking dementia progression
This study looks at biological markers to monitor how dementia changes over time. It may help understand the disease better in people with early Alzheimer's or mild cognitive impairment.
RomaAges 18 years+ - NCT07287852Enrolling by invitationPhase 2
Ginkgo biloba extract for mild cognitive impairment
This trial tests whether a specific ginkgo biloba extract (EGb761) can improve thinking and memory in people with mild cognitive impairment (MCI). It also looks at changes in blood markers related to the condition.
JerusalemAges 65 years+ - NCT07075770Recruiting
New magnetic and electrical brain stimulation for mild Alzheimer's
This trial tests a new, noninvasive treatment that combines magnetic and electrical stimulation to target a specific brain network in people with mild Alzheimer's disease. It aims to slow memory decline and improve brain function.
Rome, ItalyAges 50–85 - NCT07041450Recruiting
Screening for Alzheimer's treatment using digital tests and blood tests
This study is testing whether simple digital memory tests and blood tests can help find people who might qualify for anti-amyloid treatments (medications that target Alzheimer's-related proteins). It aims to make screening easier and faster, without needing a spinal tap or PET scan.
Greenfield Park, QuebecAges 55–90 - NCT06817902Enrolling by invitation
TMS for Early Alzheimer's Disease Pilot
This trial tests whether transcranial magnetic stimulation (TMS), a noninvasive brain treatment, can help people with early Alzheimer's or mild cognitive impairment. It aims to see if the treatment is safe and effective for slowing memory decline.
Saint Paul, MinnesotaAges 40–90
Hear when a new Alzheimer Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer dementia (ad)?
- Yes. Clin2 currently lists 143 recruiting alzheimer dementia (ad) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer dementia (ad) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer dementia (ad) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.